- Home
- Publications
- Publication Search
- Publication Details
Title
Next-Generation Integrase Inhibitors
Authors
Keywords
Efavirenz, Atazanavir, Virologic Failure, Raltegravir, Emtricitabine
Journal
DRUGS
Volume 73, Issue 3, Pages 213-228
Publisher
Springer Nature
Online
2013-02-14
DOI
10.1007/s40265-013-0015-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients
- (2012) Matthew L. Rizk et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization
- (2012) Frauke Christ et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy
- (2012) Ruxandra Calin et al. ANTIVIRAL THERAPY
- Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients
- (2012) F. Saladini et al. CLINICAL MICROBIOLOGY AND INFECTION
- Dolutegravir for the treatment of HIV
- (2012) Christine Katlama et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results
- (2012) Michael J. Kozal et al. HIV CLINICAL TRIALS
- Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors
- (2012) R Bucciardini et al. INTERNATIONAL JOURNAL OF STD & AIDS
- Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection
- (2012) Eduardo Gotuzzo et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults
- (2012) Mark R. Underwood et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
- (2012) Paul E Sax et al. LANCET
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
- (2012) Edwin DeJesus et al. LANCET
- Inhibition of the Interaction between HIV-1 Integrase and its Cofactor LEDGF/p75: A Promising Approach in Anti-Retroviral Therapy
- (2012) L. De Luca et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Tolerability of HIV integrase inhibitors
- (2012) Frederick J. Lee et al. Current Opinion in HIV and AIDS
- Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
- (2011) Sherene Min et al. AIDS
- Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
- (2011) Calvin Cohen et al. AIDS
- Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143
- (2011) Mathieu Métifiot et al. AIDS
- Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes
- (2011) Kendra E. Hightower et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK
- (2011) Jürgen K. Rockstroh et al. CLINICAL INFECTIOUS DISEASES
- Diketo Acids Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and the Reverse Transcriptase RNase H Domain
- (2011) R. Di Santo CURRENT MEDICINAL CHEMISTRY
- Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors
- (2011) Alexandra U Scherrer et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients
- (2011) I. Malet et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial
- (2011) Sébastien Gallien et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
- (2011) Jose-Luis Blanco et al. JOURNAL OF INFECTIOUS DISEASES
- Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir
- (2011) Filippo Canducci et al. JOURNAL OF INFECTIOUS DISEASES
- LEDGF Dominant Interference Proteins Demonstrate Prenuclear Exposure of HIV-1 Integrase and Synergize with LEDGF Depletion To Destroy Viral Infectivity
- (2011) A. M. Meehan et al. JOURNAL OF VIROLOGY
- Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
- (2011) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
- (2011) Jean-Michel Molina et al. LANCET INFECTIOUS DISEASES
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
- (2011) Jan van Lunzen et al. LANCET INFECTIOUS DISEASES
- Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
- (2010) Esteban Martinez et al. AIDS
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
- (2010) Roy T. Steigbigel et al. CLINICAL INFECTIOUS DISEASES
- Novel integrase inhibitors for HIV
- (2010) Nicole Prada et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures
- (2010) Alexandra U Scherrer et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
- (2010) Jeffrey L Lennox et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study
- (2010) Jose M Gatell et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial
- (2010) Andrew R. Zolopa et al. JOURNAL OF INFECTIOUS DISEASES
- Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
- (2010) Joseph J Eron et al. LANCET
- Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles
- (2010) Olivia Goethals et al. VIROLOGY
- Integrase Inhibitors: A Novel Class of Antiretroviral Agents
- (2009) Jason J Schafer et al. ANNALS OF PHARMACOTHERAPY
- Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug‐Resistant HIV‐1–Infected Patients: A Randomized Open‐Label Trial
- (2009) Nathalie De Castro et al. CLINICAL INFECTIOUS DISEASES
- HIV-1 IN Inhibitors: 2010 Update and Perspectives
- (2009) Christophe Marchand et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection
- (2009) Martin Markowitz et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Identifying and Characterizing a Functional HIV-1 Reverse Transcriptase-binding Site on Integrase
- (2009) Thomas A. Wilkinson et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
- (2009) Jeffrey L Lennox et al. LANCET
- Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen
- (2008) Marianne Harris et al. AIDS
- Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants
- (2008) M KOBAYASHI et al. ANTIVIRAL RESEARCH
- Dose–Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure
- (2008) AA Mathias et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors
- (2008) O. Goethals et al. JOURNAL OF VIROLOGY
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
- (2008) David A. Cooper et al. NEW ENGLAND JOURNAL OF MEDICINE
- Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
- (2008) Roy T. Steigbigel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started